Treatment of brain metastases
X Lin, LM DeAngelis - Journal of clinical oncology, 2015 - ascopubs.org
Brain metastases (BMs) occur in 10% to 20% of adult patients with cancer, and with
increased surveillance and improved systemic control, the incidence is likely to grow …
increased surveillance and improved systemic control, the incidence is likely to grow …
Management of brain metastases
R Soffietti, R Rudā, R Mutani - Journal of neurology, 2002 - Springer
Brain metastases occur in 20–40% of patients with cancer and their frequency has
increased over time. Lung, breast and skin (melanoma) are the commonest sources of brain …
increased over time. Lung, breast and skin (melanoma) are the commonest sources of brain …
Current management of brain metastases, with a focus on systemic options
CJ Langer, MP Mehta - Journal of clinical oncology, 2005 - ascopubs.org
Brain metastases are an important sequelae of many types of cancer, most commonly lung
cancer. Current treatment options include whole-brain radiation therapy (WBRT), surgical …
cancer. Current treatment options include whole-brain radiation therapy (WBRT), surgical …
Delivery of nanoparticles to brain metastases of breast cancer using a cellular Trojan horse
As systemic cancer therapies improve and are able to control metastatic disease outside the
central nervous system, the brain is increasingly the first site of relapse. The blood–brain …
central nervous system, the brain is increasingly the first site of relapse. The blood–brain …
Therapeutic management of brain metastasis
ECA Kaal, CGJH Niël, CJ Vecht - The Lancet Neurology, 2005 - thelancet.com
This review focuses on the management of brain metastases. The four main modes of
therapy are discussed: whole brain radiation therapy (WBRT), surgery, radiosurgery, and …
therapy are discussed: whole brain radiation therapy (WBRT), surgery, radiosurgery, and …
[HTML][HTML] Prospective trial on topotecan salvage therapy in primary CNS lymphoma
L Fischer, E Thiel, HA Klasen, J Birkmann, K Jahnke… - Annals of oncology, 2006 - Elsevier
Background: Standard salvage therapy has not been established for recurrent primary
central nervous system lymphoma (PCNSL). We report the final results of a prospective …
central nervous system lymphoma (PCNSL). We report the final results of a prospective …
In vitro chemo-and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways
AC Kraus, I Ferber, SO Bachmann, H Specht… - Oncogene, 2002 - nature.com
Most small cell lung cancer (SCLC) patients relapse within 12 months of starting
combination chemotherapy plus radio-therapy, due to the development of acquired chemo …
combination chemotherapy plus radio-therapy, due to the development of acquired chemo …
Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix
M Frumovitz, MF Munsell, JK Burzawa, LA Byers… - Gynecologic …, 2017 - Elsevier
Objectives To assess if the combination of topotecan, paclitaxel, and bevacizumab (TPB)
was active in recurrent SCCC and to compare the survival of patients with SCCC who …
was active in recurrent SCCC and to compare the survival of patients with SCCC who …
Response of asymptomatic brain metastases from small-cell lung cancer to systemic first-line chemotherapy
T Seute, P Leffers, JT Wilmink… - Journal of clinical …, 2006 - ascopubs.org
Purpose The purpose of this study was to investigate the radiologic response of
asymptomatic brain metastases (BM) from small-cell lung cancer (SCLC) to first-line …
asymptomatic brain metastases (BM) from small-cell lung cancer (SCLC) to first-line …
Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiation: a multicentre phase II study
A Korfel, C Oehm, J Von Pawel, U Keppler… - European Journal of …, 2002 - Elsevier
The purpose of this multicentre phase II study was to evaluate the efficacy and toxicity of
topotecan in pretreated patients with small-cell lung cancer (SCLC) who relapsed with …
topotecan in pretreated patients with small-cell lung cancer (SCLC) who relapsed with …